Optibrium and AstraZeneca Sign Agreement for Global Licence of StarDrop
Optibrium, a developer of software for drug discovery, today announced that AstraZeneca has signed an agreement to license Optibrium’s StarDrop software. The agreement will see the global deployment of StarDrop and the ADME-QSAR and Auto-Modeller modules to AstraZeneca’s researchers.
StarDrop is a software suite that helps to deliver optimally balanced, effective drugs. By quickly highlighting diverse, high-quality compounds, StarDrop dramatically reduces the time it takes to find effective leads and then transform them into candidate drugs, which will have a high probability of success downstream.
StarDrop works by evaluating complex data, which is often uncertain because of experimental variability or predictive error. In scoring this data, the software brings confidence and intuitive simplicity to decision-making: guiding and validating the direction of research projects and which compounds are prioritised. Its instantly interactive tools then enable researchers to efficiently explore ways to further improve their chemistries.
StarDrop’s ADME QSAR plug in module enables the prediction of a broad range of ADME and physicochemical properties using a suite of high-quality QSAR models. The Auto-Modeller module gives novice and expert users alike access to the tools needed to produce validated, predictive models of their own chemistry and data.
Dr Matthew Segall, Optibrium’s CEO, commented: “We are delighted that AstraZeneca has selected StarDrop to help guide their global drug discovery research efforts and we look forward to collaborating with their scientists to integrate our unique technology with their in-house infrastructure.”
Dr Nicholas Tomkinson, AstraZeneca Informatics, commented: “StarDrop’s unique approach to multi-parameter optimization and intuitive user interface complement our in-house efforts in this area, and enable our interdisciplinary design teams to target compounds with a balance of properties required for their project objectives”.
Dr Patrick Barton, AstraZeneca DMPK, added: “Drug metabolism, together with the prediction of human kinetics and dose, is a multi-objective optimization problem. We seek a compromise between potency, selectivity, pharmacokinetic and toxicological profiles to discover a safe and efficacious drug. Currently, we undertake an empirical approach to optimization, which relies on experience and often leads to inconsistent decision-making. The introduction of StarDrop will improve objective decision making and decrease the timelines of our projects.”
For further information on Optibrium and StarDrop, please visit www.optibrium.com, contact [email protected] or call +44 1223 815 900.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance